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Biochemical and pharmacogenetic properties of selected steroid 5α-reductase
SNPs and haplotypes
Construct Vmax
(nmol×min−1×mg−1)
Ki finasteride
(nM)
Normal (wt) SRD5A2 cDNA 1.9 60
A49T SNP 9.9 180
V89L SNP 1.1 113
A49T/V89L compound heterozygote 5.5 150
A49T-V89L double mutant
(minihaplotype)
2.9 48
These data were originally published in [3]. They are reproduced by permission
of the publisher.Unexpected biochemical and pharmacogenetic
consequences of SNPs and haplotypes: A cautionary tale for
human molecular genetics and epidemiology
To the Editor,
Haplotypes have recently become popular and much
discussed as new tools in human molecular genetics,
molecular epidemiology, etc. (e.g., [1,2] and many more in
this and other journals), although the success stories thus far
have been few, e.g., [1]. This journal has played a prominent
role in promoting this novel strategy. We wish to remind the
human molecular genetics and epidemiologic research
communities that human genetic variants, such as SNPs
(single nucleotide polymorphisms) and combinations thereof,
i.e., haplotypes, may result in functional consequences, such
as biochemical and pharmacogenetic effects, that in turn will
influence phenotypes directly (or indirectly), be under
selection, etc. In other words, SNPs and haplotypes will
not always simply be neutral genetic markers but will
sometimes be functional alleles themselves. This situation
has important consequences when one may be looking at the
association and/or linkage of SNPs and haplotypes with
phenotypes.
We present here two instructive examples of unexpected
biochemical and pharmacogenetic consequences in the human
steroid 5α-reductase type II (SRD5A2) gene that illustrate the
general caveats we made above (Table 1).We examine here in
some detail the biochemical and pharmacogenetic properties of
two common SRD5A2 variants, the A49T (alanine at codon
49 replaced by threonine) and V89L (valine 89 to leucine; see
Table 1 and [3]) SNPs, and the resulting haplotype as well as
the compound heterozygote situation. In these previously
reported experiments, each variant was reconstructed by site-
directed mutagenesis, confirmed by sequencing, transfected,
and assayed for its enzyme activity [3]. Appropriate controls
were carried out as reported in Makridakis et al. [3]. First, the
enzyme activity (reported as the apparent maximal reaction
rate, Vmax, in Table 1) shows the expected average (i.e.,
[9.9+1.1]/2=5.5 nmol/min/mg) for the compound heterozy-
gote A49T/V89L, but a much lower value, 2.9 nmol/min/mg,
for the double mutant A49T–V89L, which is a minihaplotype
(Table 1). This suggests that the V89L variant is a partial
dominant over A49T in this model haplotype setting. In
contrast, in the heterozygote situation, the subunits are0888-7543/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygeno.2006.06.013oblivious to each other, i.e., they appear to act as independent
monomers since the average of the two enzyme activities is
observed (Table 1). Oligomerization of mutant or polymorphic
subunits in compound heterozygote situations may be a further
complication in other cases, which should also be borne in
mind. When looking at pharmacogenetic effects, reported as
the apparent inhibition constant, Ki, in Table 1, we found that
the compound heterozygote A49T/V89L again behaves
essentially as predicted, resulting in the average of the two
individual SNP, A49T and V89L, Ki's (i.e., [180+113]/
2=146.5 or about 150 nM as reported in Table 1). However,
the double mutant A49T–V89L (or minihaplotype) results in a
totally new Ki of 48 nM (Table 1). This result is unexpected
since it is completely different, namely much lower, than any
of the other Ki's. The Ki data also suggest that and—not
unexpectedly and—polymorphisms may interact with each
other in polypeptides encoded by haplotypes, resulting in novel
properties for the resulting protein. These two unexpected
biochemical and pharmacogenetic findings dramatically illus-
trate the importance of determining and considering the
functional consequences of individual SNPs and haplotypes.
These data highlight the importance of establishing the
functional consequences of SNPs and haplotypes [4] and
bearing these often unexpected results in mind in association
and linkage studies.
In conclusion we remind the readership of this journal (and
of the human molecular genetics and epidemiology community
in general) of the functional consequences of SNPs and
haplotypes, which should be considered in association and
linkage studies. These consequences should be borne in mind
when designing studies and in fact these effects should be
rigorously established where feasible.
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